

**Serious Adverse Event Reporting**
**ANRS 12249 Initial SAE Notification**

Completed forms must be sent to  
ANRS within 48 hrs.  
Email: [pharmacovigilance@anrs.fr](mailto:pharmacovigilance@anrs.fr)  
Fax: +33 153 946 002



00093277

SAE No.

SAE Visit Date

20140113

Initial Notification Date

20140121

Notification time

**1. Patient details**

TasP ID

29981

Name

J.M

Sex

Male

● Female

Date of birth

19751225

Enrolment date

20130708

**DATA CAPTURED**

2014-01-23

DC QC

**2. Measurements**

Height

161 Cms

Last known: Weight

51.0

Kgs

Weight Date

20140113

CD4 count

184

CD4 Date

20140113

Viral Load

695

Viral Load Date

20140113

**3. By which criteria is this adverse event considered to be "Serious"?**

Tick all that apply

- ☐ Resulted in death → Date of death Probable cause
- ☐ Life threatening (i.e. at risk of death at time of event)
- ☐ Caused or prolonged hospitalisation (not elective hospitalisation for a pre-existing condition)
- ☐ Persistent or significant disability / incapacity
- ☐ Congenital abnormality / birth defect
- ☒ Grade 4 clinical and biological events
- ☐ Other serious, medically-important condition → Specify

**4. Details of SAE**

Enter each adverse event (e.g. symptom, sign, syndrome or diagnosis) on a separate line

Event Name
Date investigator  
became aware
Date of onset of SAE

1. ANAEMIA 20140116 20140113

2.

3.

4.

5.

**5. Description of SAE**

Include details of body site, relevant laboratory tests, treatments received and relevant medical history.

Attach copies of any relevant hospital records, laboratory test results etc.

Macrocytic (MCV 130), hyperchromic (MCH 42) anaemia (Hb 61g/dL)  
noticed during routine blood test

## 6. Medications

List all drugs taken (or prescribed) before occurrence of SAE

Generic Name	Daily dose	Route of administration	Indication	Date started	Date stopped	Causality assessment	Expected reaction? (BNF/SPC)	Action taken
1. TENOFOVIR	300MG	PO	HW	20111110		<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input checked="" type="radio"/> Yes <input type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
2. LAMIVUDINE	300MG	PO	HW	20111110		<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input checked="" type="radio"/> Yes <input type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
3. EFAVIRENZ	600MG	PO	HW	20111110		<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input checked="" type="radio"/> Yes <input type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
4. COTRIMOXAZOLE	PO	PCP PROPHYLAXIS		20130708		<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input checked="" type="radio"/> Yes <input type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
5.						<input type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
6.						<input type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop

## 7. Other causes of SAE, if unrelated to drugs mentioned in Section 6 above

7a. According to the physician, is this SAE likely to be related to participation in the research? Yes ☐ No ☒

7b. According to the physician, is this SAE related to any causes other than the research? Yes ☒ No ☐  
This includes the patient's medical history

Describe

Multiple ART defaults,  
cannot exclude Bone Marrow  
Suppression from Cotrimoxazole

## 8. SAE Outcome

Died

Unknown to date

☒ Ongoing

Improved

Recovered

→ A complementary SAE notification must be submitted within 8 days

→ Date of recovery

Recovered without sequelae  
or

Recovered with sequelae  
→ Describe

## Physician reporting SAE

Name

DR CALYNSI MUKA

Signature

*[Signature]*

Date form completed

20130120